Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ProQR Therapeutics N.V.
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
October 28, 2026
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
September 23, 2026
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
September 9, 2026
ProQR to Participate in Upcoming Investor Conferences in September 2026
September 2, 2026
ProQR Announces Second Quarter 2026 Operating and Financial Results
August 13, 2026
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
June 25, 2026
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
May 23, 2026
ProQR Announces First Quarter 2026 Operating and Financial Results
May 22, 2026
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
May 22, 2026
1
2
Next Page
→